Quantum News
Sign InSign Up
Back to News
research

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Beam Therapeutics unveiled positive Phase I/II results for BEAM-302, its base-editing therapy for alpha-1 antitrypsin deficiency (AATD), marking a milestone for in vivo gene editing. The trial demonstrated sustained AAT protein level increases in patients, with durable responses up to 48 weeks post-treatment, suggesting potential long-term efficacy for this genetic liver disease. CEO John Evans highlighted the therapy’s precision base-editing approach, which corrects the SERPINA1 gene mutation without permanent DNA cuts, reducing off-target risks compared to CRISPR-Cas9. Chief Medical Officer Amy Simon noted no serious adverse events linked to BEAM-302, reinforcing its safety profile as the company prepares for Phase III trials in 2027. Analysts questioned scalability and manufacturing, with leadership emphasizing optimized delivery systems and partnerships to accelerate commercialization if approved.
AI Audio Summary
0:00 / 0:00
Click to play
quantum computing images (3).jpg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.12K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency March 25, 2026 8:00 AM EDT Company Participants Holly Manning - Vice President of Investor Relations & External CommunicationsJohn Evans - CEO & DirectorAmy Simon - Chief Medical OfficerGiuseppe Ciaramella - President Conference Call Participants Jeffrey TeckmanAdhirath Sikand - Evercore ISI Institutional Equities, Research DivisionMaurice Raycroft - Jefferies LLC, Research DivisionSamantha Semenkow - Citigroup Inc., Research DivisionEric Schmidt - Cantor Fitzgerald & Co., Research DivisionLut Ming Cheng - JPMorgan Chase & Co, Research DivisionYanan Zhu - Wells Fargo Securities, LLC, Research DivisionMani Foroohar - Leerink Partners LLC, Research DivisionLuca Issi - RBC Capital Markets, Research DivisionAngela Qian - Canaccord Genuity Corp., Research DivisionMyles Minter - William Blair & Company L.L.C., Research Division Presentation Operator Good morning, and welcome to Beam Therapeutics Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Beam's request. I would now like to turn the call over to Holly Manning, Vice President of Investor Relations and External Communications. Holly ManningVice President of Investor Relations & External Communications Thank you, operator. Good morning, everyone, and welcome to Beam's conference call to review top line clinical data from the Phase I/II trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency. You can access slides for today's call by going to the Investors section of our website, beamtx.com. With me on the call today with prepared remarks are John Evans, our Chief Executive Officer; Dr. Amy Simon, our Chief Medical Officer; Dr. Jeff Teckman from St. Louis University; and Dr.

Giuseppe Pino Ciaramella, our President. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements for purposes of the safe harbor provision under

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.